INSTITUTE BIOSAFETY COMMITTEE
Chairperson: Chunling Dai

Minutes

Institution: New York State Institute for Basic Research in Developmental Disabilities (IBR)

Meeting Date: 10.15.2025

Meeting Time: 1:00 PM

Meeting Type: Virtual

IBC Members Present:

1. Chunling Dai (*IBC Chair*)
2. Karen Amble (*IBC Member/IBR Deputy Director*)
3. Augusta D'Amico (*IBC Member/Director of Clinical Services*)
4. Lorena Legisi-Sejdaras (*Biological Safety Officer/Director, Office of Laboratory Safety and Training*)
5. Xue-Ying He (Lab Rep.)
6. Fang Du (Lab Rep./Animal Expert)
7. Sonal Goswami (Lab Rep.)
8. Ashfaq Sheikh (Lab Rep.)
9. Wen Hu (Lab Rep./Animal Expert)
10. Christopher Corbo (Local Non-affiliated Member)
11. Michael Eisenbraun (Local Non-affiliated Member)

IBC Members Absent:

1. Dorota Ziemnicka (Lab Rep.)

Quorum: Present

Other Individuals in Attendance: None

Call to Order: 1:06 PM

Conflicts of Interest:

The Chair reminded all members present to identify any conflicts of interest as each registration is reviewed.

Review and Approval of Previous Meeting Minutes:

A member moved to approve the September 17, 2025, minutes, as written. Another member seconded the motion.

IBC Votes:
- For: 9
- Against: 0

- Abstain: 0

Review of Prior Business:

- Inspections of Safety Showers in the main building are in progress.

2025 Annual Review:

2020-001	T. Adayev	Feasibility of newborn screening for Fragile X syndrome using FMRP quantitation in newborn dried blood spots.	**Minor Change**
2020-002	T. Adayev	Genotype-specific expression of FMRP during prenatal and early neonatal stages of human development.	**Minor Change**
2020-003	T. Adayev	Molecular-clinical correlations across FMR1 genotypes.	**Minor Change**

New Applications:

A) IBC-2025-005 Electron Microscopy (Core Specimen Preparation) by Dr. Sararose Guariglia.

Project Overview:

Reviewer 1- This project involves creating a standard operating procedure (SOP) that outlines how to prepare biological specimens for imaging with an electron microscope. Once the SOP is developed and approved, the laboratory and collaborating researchers will use it indefinitely to ensure consistent, high-quality sample preparation. MATERIALS: Paraformaldehyde, glutaraldehyde, osmium tetroxide, ethanol, acetone, Epon, London, or Spurr's resin components, uranyl acetate, lead citrate. TECHNIQUES:
Fixation, dehydration, resin embedding, sectioning and staining.
Recommendation: Approved

Reviewer 2-
For this application (IBC 2025-005), I do not have any concerns about the recombinant DNA, infectious agents, or chemicals of interest. My recommendation is approval.

Biological Safety Officer

a) NIH Guidelines Section
   - None

b) Risk Assessment and Discussion:
   - No agent, such as an organism or host vector system, is part of this project.
   - No experimental manipulations, such as tissue culture, will be employed in this project.
   - There are chemicals of interest that are part of this project. All the disposal methods and safety precautions are explained in detail in the Risk Assessment form. The laboratory is equipped with a chemical fume hood and a biosafety cabinet that will be used as necessary. The investigator will use all the

necessary personal protective equipment for a BSL-2 protocol. Respiratory protection is necessary for conducting this work.

c) Training:
- The principal investigator meets all training requirements.

d) Biosafety Level Assignment:
- The biosafety containment levels at which each of the project's operations will occur are BSL-2.

IBC Votes:

A member made a motion to approve the project, which was seconded by another member.

Votes:
- For: 9
- Against: 0
- Abstain: 0

B**)** IBC-25-57 Randomized controlled trial of Propranolol for aggression, self-injury, and severe disruptive behavior in adolescents and adults with autism by Dr. J Helen Yoo

Reviewer 1-
To perform a randomized double-blind, placebo-controlled, practical study of high-dose propranolol as a treatment for problem behavior associated with ASD, including aggression, self-injury, and severe disruptive behavior.
MATERIALS: Propranolol, gloves
TECHNIQUES Urine collection
Recommendation -Approved

Reviewer 2-
I reviewed the application as presented and do not have any questions at this time. All protocols are in place, and I move to approve.

Biological Safety Officer-

d) NIH Guidelines Section
- None

e) Risk Assessment and Discussion:
- No agent, such as an organism or host vector system, is part of this project.
- No experimental manipulations, such as tissue culture, will be employed in this project.

f) Chemicals of interest
- None

g) Training:
- The principal investigator meets all training requirements.

d) Biosafety Level Assignment:
- The biosafety containment levels at which each of the project's operations will occur are BSL-2.

IBC Votes:

A member made a motion to approve the project, which was seconded by another member.

Votes:

- For: 9
- Against: 0
- Abstain: 0

New Business:

- None

Review of Incidents:

(The NIH Guidelines require that significant incidents, violations, and research-related accidents and illnesses be reported to NIH OSP.)

- Nothing to report at this time.

Inspections/Ongoing:

(Section IV-B-2-b-(5) of the NIH Guidelines requires IBCs to periodically review institutions' research to ensure compliance with the NIH Guidelines.)

- Annual inspections of IBR's main building are currently ongoing.

Public Comments:

- There were no public comments.

Adjournment:

Ms. Amble moved to adjourn the meeting at 1:19 PM. Ms. D'Amico seconded the motion.

The next meeting is scheduled for November 19, 2025, via WebEx.